Abstract | OBJECTIVES: Although active against free-floating bacteria, vancomycin displays a poor activity against organisms embedded within the biofilm surrounding implanted devices. Dalbavancin is a novel glycopeptide antibiotic with strong activity against staphylococci and a long half-life that allows for once-a-week dosing. The objective of this animal study was to examine the ability of dalbavancin and vancomycin to prevent Staphylococcus aureus colonization of devices. METHODS: RESULTS: The rates of device colonization were comparable in the vancomycin (53%) and control (47%) groups, whereas only 28% of devices in the dalbavancin group became colonized. There was a trend (although not statistically significant) toward a lower rate of device colonization following receipt of dalbavancin vs. vancomycin (P = 0.07) or saline (P = 0.02). CONCLUSIONS: The demonstrated efficacy of dalbavancin in this animal study suggest that this novel antibiotic may have an important role in the prevention and treatment of device-related infection.
|
Authors | R O Darouiche, M D Mansouri |
Journal | The Journal of infection
(J Infect)
Vol. 50
Issue 3
Pg. 206-9
(Apr 2005)
ISSN: 0163-4453 [Print] England |
PMID | 15780414
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Glycopeptides
- Teicoplanin
- Vancomycin
- dalbavancin
|
Topics |
- Animals
- Anti-Bacterial Agents
(therapeutic use)
- Equipment Contamination
(prevention & control)
- Evaluation Studies as Topic
- Female
- Glycopeptides
(therapeutic use)
- Prosthesis-Related Infections
(prevention & control)
- Rabbits
- Staphylococcal Infections
(prevention & control)
- Teicoplanin
(analogs & derivatives)
- Vancomycin
(therapeutic use)
|